2014
Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction
Ersboll M, Schulte PJ, Al Enezi F, Shaw L, Køber L, Kisslo J, Siddiqui I, Piccini J, Glower D, Harrison JK, Bashore T, Risum N, Jollis JG, Velazquez EJ, Samad Z. Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction. The American Journal Of Cardiology 2014, 115: 86-92. PMID: 25456876, DOI: 10.1016/j.amjcard.2014.09.049.Peer-Reviewed Original ResearchConceptsModerate aortic stenosisAortic stenosisMild aortic stenosisVentricular ejection fractionMean gradientHemodynamic progressionEjection fractionClinical variablesLeft ventricular ejection fractionSevere aortic stenosisBaseline clinical variablesSubset of patientsRate of progressionEchocardiographic surveillanceRenal dysfunctionUnselected cohortAccelerated progressionLongitudinal linear regression modelsCurrent guidelinesDisease progressionRetrospective analysisPatientsSignificant interactionProgressionBaseline
2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney International 2011, 81: 568-576. PMID: 22189843, DOI: 10.1038/ki.2011.417.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBiomarkersBlack or African AmericanBlood PressureCalcium Channel BlockersCardiovascular DiseasesChi-Square DistributionCreatinineDiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionIncidenceKaplan-Meier EstimateKidneyKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesUp-RegulationConceptsHigh cardiovascular riskNon-black patientsSerum creatinineCardiovascular riskEnd-stage renal diseaseBlood pressure goalsHypertensive black patientsAcute hemodynamic effectsEffective antihypertensive treatmentKidney disease progressionGlomerular filtration rateDouble-blinded mannerEvent-driven trialDisease end pointsACCOMPLISH trialAntihypertensive treatmentRenal outcomesEGFR lossHemodynamic effectsRenal diseaseBlack patientsBlack ethnicityFiltration rateDisease progressionPatients
2006
Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
Liu PP, Maggioni A, Velazquez EJ. Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients. Journal Of The Renin-Angiotensin-Aldosterone System 2006, 7: s19-s22. PMID: 16986231, DOI: 10.3317/jraas.2006.019.Peer-Reviewed Original ResearchConceptsAng II receptor blockersHeart failureLV dysfunctionMyocardial infarctionStrong therapeutic rationaleUse of valsartanII receptor blockersLeft ventricular dysfunctionHeart failure patientsPost-MI patientsMain effector mechanismPost-myocardial infarctionLarge-scale trialsRAAS blockadeAldosterone systemReceptor blockersVentricular dysfunctionAssociated morbidityFailure patientsFrequent complicationSuch patientsACE inhibitorsSignificant morbiditySuch therapyDisease progression